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T
his is the third of four articles sum-
marizing presentations at the sev-
enth World Congress on the Insulin
Resistance Syndrome, held in San Fran-
cisco,California,on5–7November2009.
This article pertains to the kidney, the
liver, and insulin resistance.
The kidney and insulin resistance
Eberhard Ritz (Heidelberg, Germany)
discussed insulin resistance (IR), meta-
bolic syndrome, and the kidney, noting
that obesity, which causes IR, is currently
at epidemic levels and begins in child-
hood. Ritz also pointed to the association
of obesity with hypertension, dyslipide-
mia, diabetes, and a variety of complica-
tions. Chronic kidney disease (CKD) is
associated with obesity (1), with a BMI
25 kg/m
2 in young adulthood tripling
the risk of subsequent CKD (2) and end-
stage renal disease (3) in a fashion com-
parable with the more recognized
association of obesity with coronary dis-
ease. Both high and low birth weight also
increase CKD risk (4) since intrauterine
growth retardation is a risk factor for de-
creased renal function among young
adults(5).Theeffectofobesityvarieswith
ethnicity as seen with CKD beginning to
increase at a BMI of 22 kg/m
2 among Jap-
anese subjects (6).
The link between obesity and end-
stage renal disease appears in part due to
diabetes and hypertension (7), but there
arealsothedirecteffectsofoverweighton
the kidney (8). Proinﬂammatory and
growth-promoting cytokines associated
withobesitymighthavedirectadversere-
nal effects (9). A mechanism may be the
association of obesity and IR with hyper-
ﬁltration (10) and the consequent renal
damage based on sodium excess, which
may cause glomerulomegaly and may be
in part an effect of IR. Ritz noted that ex-
ogenous insulin does not directly cause
these effects (11). Obesity is associated
with increased intraglomerular pressure,
which increases the ﬁltration fraction
(12).Weightlosswithbariatricsurgeryin
morbid obesity decreases the glomerular
ﬁltration rate and renal plasma ﬂow and
reduces albuminuria (13). Renal sensitiv-
ity to aldosterone increases in the setting
of inﬂammation and oxidative stress, ad-
ditional potential causative factors, with
adipocyte-derived factors exacerbating
podocyte injury from aldosterone over-
production (14), which can be inhibited
by aldosterone antagonists such as
eplerenone (15). The increased activity of
11- hydroxysteroid dehydrogenase type
1 in IR and type 2 diabetes leading to in-
creased cortisol action may also play a
role. IR is associated with increased total
body sodium and with sodium-sensitive
hypertension. The sodium reabsorption
due to insulin is not, however, lessened
by IR, which blocks insulin-induced va-
sodilation and leads to elevation in blood
pressure. Low adiponectin levels may in-
creasealbuminuriaandoxidantstressina
fashion ampliﬁed by diabetes (16). There
is evidence that decreased telomere
length,indicativeoftissueaging,ispoten-
tiated in adipose tissue by obesity (17).
The ﬁnding of a correlation between
waist circumference and albuminuria
(18) has led to the notion that visceral fat
isparticularlyinjurioustothekidney(19)
since the waist-to-hip ratio is superior to
BMI as a predictor of CKD risk (20). Met-
abolic syndrome is associated with renal
insufﬁciency (21). The number of meta-
bolic syndrome factors is associated both
with microalbuminuria and CKD (22)
andwithdiabeticnephropathyinindivid-
uals with type 1 diabetes (23).
Even very early abnormalities of
glucose metabolism that do not reach
impaired glucose tolerance/impaired
fasting glucose are associated with renal
insufﬁciency (24). A number of patho-
logical features characterize the kidney
in obesity (25), including glomerular
hypertension, endothelial dysfunction,
vasoconstriction, and expansion of
mesangial matrix (26). Obesity is asso-
ciated with reduced podocyte number,
segmentalglomerulosclerosis,glomeru-
lomegaly, and interstitial and arterial
abnormalities (27). Obesity is also asso-
ciatedwithrenalcancer,nephrolithiasis
(28), and focal segmental glomerulo-
sclerosis. There is evidence that obese
individuals with IgA glomerulonephri-
tis have poorer outcomes (29).
Urate, fructose, and insulin
resistance
Richard Johnson (Denver, Colorado) dis-
cussed uric acid, fructose, and the meta-
bolic syndrome, which are the subjects of
his book for the general public entitled
“The Sugar Fix.” He noted that the in-
crease in obesity in the U.S. began in the
1800s (30); that the prevalence of hyper-
tension increased from 10% in 1939, to
25.3% in 1975, 28.9% in 1990, and
31.3% in 2000; and that there has been a
dramatic increase in diabetes in the U.S.
(31). In Kuwait, 40% of adults have dia-
betes and there has correspondingly been
a tremendous increase in cardiovascular
disease (CVD). Angina was rare in the
1880s, with coronary artery disease ﬁrst
described in 1911, but it became increas-
ingly common in the U.S. in the 1920s.
According to Johnson, there were only
500 cardiologists in the U.S. in 1950, and
today there are more than 30,000. Car-
diovascular mortality has recently de-
creased somewhat, not because of the
reduction in CVD but rather because of
improvements in the late-stage treat-
ments of the disease.
The notion of a relationship be-
tween diet and CVD has developed over
the past century. Ancel Keys addressed
a potential mechanism by reviewing the
data from a well-known study of the ef-
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(32).Certainlylow-fatdietsreducecho-
lesterol, Johnson commented, but these
diets “really don’t work” in comparison
to control diets, as shown in the huge
(nearly 50,000 subjects) Women’s
Health Initiative Randomized Con-
trolled Dietary Modiﬁcation Trial (33).
A possible mechanism is the relation-
ship of sugar intake to CVD. Haven Em-
erson, an early exponent of novel
approaches to public health, presented
data in the early 1900s showing that
the prevalence of diabetes in New York
had increased from 2.8 to 19 cases per
100,000. There have been parallel in-
creasesinobesityanddietarysugar,and
Johnson pointed in particular to the ef-
fects of high dietary fructose, with the
metabolism of fructose by fructokinase
not under feedback inhibition by ADP
and depending ATP while increasing
levels of AMP, which in turn increases
uric acid. Fructose also increases tri-
glyceride levels (34).
An association of hyperuricemia with
hypertension has long been recognized
and Johnson cited an article from 1879
that stated “people who are subject to this
high blood pressure…frequently belong
to gouty families” (35). It has been sug-
gested that hyperuricemia might be
caused by obesity or by factors related to
IR, but Johnson discussed the idea that
there may be a causal relation of urate to
CVD. Most mammals have low levels of
uratebecauseoftheenzymeurateoxidase
(uricase), which is not expressed in man.
When rats are given an uricase inhibitor,
their blood pressure increases, an effect
blocked with allopurinol. Urate has pro-
oxidant intracellular effects, which re-
duce nitric oxide levels, stimulate the
renin-angiotensin-aldosterone system,
and induce renal microvascular lesions
independent of blood pressure. Renal mi-
crovascular disease induces sodium-
sensitive hypertension. In animals fed a
low salt diet, an uricase inhibitor in-
creases blood pressure and leads to the
development of sodium-sensitive hyper-
tension (36). A number of studies show
uratelevelstoberiskfactorsforhyperten-
sion (37). This, Johnson noted, occurs
most commonly in cases of newly diag-
nosed hypertension. Indeed, children
with newly diagnosed hypertension have
highuratelevels(38).Furthermore,when
newly diagnosed hypertensive adoles-
cents were treated with allopurinol, two-
thirds(86%ofthosewhoseuricacidlevel
was 5 mg/dl, perhaps reﬂecting a group
with better adherence) became normo-
tensive(39).Johnsonspeculatedthaturic
acid reduces nitric oxide and decreases
skeletal muscle microvascular blood ﬂow
with consequent decreases in glucose up-
take, which contributes to IR. Urate also
induces a diabetic phenotype in adipo-
cytes (40). In Johnson’s studies, allopuri-
nol improved insulin sensitivity, lowered
triglycerides, and reduced weight gain.
As might be expected, Johnson said
urate is a risk factor for diabetes (41). He
suggested that metabolic syndrome is a
disease, and the increase in urate over the
past century has contributed to the prev-
alence of the disease. He presented data
from a study of 76 men given 200 g fruc-
tose daily for 2 weeks, which increased
blood pressure and triglycerides and re-
duced hormone-sensitive lipase and
insulin sensitivity. Administration of allo-
purinol prevented the increase in blood
pressure and the development of meta-
bolic syndrome. Fructose may have been
a survival factor in aiding hominids to de-
velop IR, allowing adaptation to starva-
tion without giving rise to high urate—
but this is not relevant in men on a high
sodium, high purine, high fructose diet
withelevatedlevelsofurate.Accordingto
Johnson, fructose now comprises 15–
25% of the U.S. diet and may be the driv-
ing force leading to CVD.
Nonalcoholic fatty liver disease
and IR
Arun Sanyal (Richmond, Virginia) dis-
cussed nonalcoholic fatty liver disease
(NAFLD), characterized by nonalcoholic
steatohepatitis (NASH), hepatocyte in-
jury, inﬂammation, ﬁbrosis, and cirrho-
sis. Steatohepatitis is not simply a
combination of fat and inﬂammation, but
involves speciﬁc abnormalities including
cytologic ballooning, Mallory bodies
composed of eosinophilic material, and
pericellular ﬁbrosis. We are just begin-
ning to understand the underlying pro-
cesses causing tissue repair that leads to
resolution in some and disease progres-
sion to cirrhosis in others (15–20% of
patients) with mechanisms of hepatic ﬁ-
brosis including oxidative and cytokine
stress activating stellate cells, potentially
withaﬁbrosis-increasingeffectofinsulin.
The liver has high regenerative capacity,
and the role of hepatic stem cells is being
explored.
Hepatic fat in NAFLD is predomi-
nantly triglycerides made up of n-7 fatty
acids with decreases in the n-3 and n-6
precursors, which perhaps reﬂect abnor-
malities of intrahepatic metabolism with
increased utilization of arachidonic acid
and production of proinﬂammatory li-
poxygenase products (42). This suggests
increasedstearoylCoAdesaturaseactivity
under the inﬂuence of hyperinsulinemia,
which is not downregulated in IR. The
balance of fat synthesis and import
against utilization and export determines
hepatic fat content (43) so that the histo-
logic ﬁndings of a fatty liver may be re-
garded as representing the protective
responses to large amounts of potentially
toxic fatty acids entering the liver. Tran-
scriptional regulation of this process in-
clude the nuclear receptors liver X
receptor, farnesoid X receptor, and the
peroxisome proliferator–activated recep-
tors, which in turn are regulated by insu-
lin, adiponectin, tumor necrosis factor-,
resistin,andmanyothercytokines,which
Sanyal summarized as being “anything
but simple!”
A potentially important ﬁnding in
NAFLD has been an increase in hepatic
freecholesterol,perhapsproducedbyup-
regulation of hydroxymethylglutaryl-
CoA reductase and sterol regulatory
element–binding protein 2, related to
downregulation of the microRNA mir122
(44)andinducingapoptosis.Freecholes-
terolisusuallyesteriﬁedtocholesteroles-
ter. In NAFLD, reverse esteriﬁcation of
cholesterolestertofreecholesteroloccurs
with a reduction in the export of free cho-
lesteroltoLDLbecauseofdecreasedLDL-
receptor levels, while the conversion of
free cholesterol to bile acids is downregu-
lated. There is also downregulation of
cholesterol efﬂux via the transport sys-
tems ATP-binding cassette A1 and G1,
creating“aperfectstorm”forexacerbating
liver injury.
Further mechanisms of hepatocyte
injury include oxidative stress (45), re-
ﬂecting increased lipid peroxidation from
mitochondrial dysfunction, iron over-
load, and perhaps reduced antioxidative
defense mechanisms. Abnormalities of
mitochondria in NAFLD are seen with
paracrystalline inclusions on microscopy,
suggesting a defective electron transport
system leading to increased free radical
expression. Lipid-induced apoptosis
leads to ceramide accumulation, causing
further apoptosis (46,47). The unfolded
protein response, a cellular process oc-
curring with overload of the endoplasmic
reticulum,occursinstatesofhighprotein
synthesis and inadequate ATP availability
and leads to an adaptive response with
decreasedproteinsynthesisandincreased
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itol-requiring enzyme-1 pathway mediat-
ing this process shows particular
abnormality in 20% of patients. These
patientsmaycomprisethesubsetwiththe
increasedlikelihoodofprogressiontocir-
rhosis as reduction in protein synthesis
appears to promote recovery while in-
creased protein degradation leads to fur-
ther cellular toxicity. This may be
mediated by two other microRNAs, mir-
34A and mir 451 (45).
Jeff Schwimmer (San Diego, Califor-
nia) discussed clinical consequences and
diagnostic challenges in NAFLD, distin-
guishing fatty liver from NAFLD and, in
turn, NAFLD from NASH. NAFLD in-
cludes a spectrum of disorders ranging
from steatosis to steatohepatitis with or
without degrees of ﬁbrosis extending to
cirrhosis. Most children with NAFLD are
overweight or obese. Analysis of liver his-
tology from 1,000 autopsy specimens
mainly obtained after motor vehicle acci-
dents showed the presence of NAFLD in
10%atage10–14yearsand18%atage
15–19 years. There was a greater fre-
quency in boys than girls and a lower fre-
quency in blacks and a somewhat higher
frequencyinHispanicsthaninwhitesand
Asians. Of those with NAFLD, 60% were
obese, 20% overweight, and 20% normal
weight (48). Short of histology, with fatty
liver deﬁned by 5% fat content (normal
liver fat content is 1%), clinical testing is
imperfect.Althoughalaninetransaminase
(ALT)tendstobeelevatedinNAFLD,and
the majority of obese adolescents with
ALT 35 have fatty liver (based on mag-
netic resonance imaging [MRI]) and the
majority of obese adolescents with ALT
35 have a normal MRI (49), Schwim-
mer noted, “Being obese and having an
elevated ALT does not automatically
equal NAFLD.” Further, MRI studies
show that “the ability to distinguish none
from mild [on ultrasound] is actually
quite poor” (50,51). MRI assessment of
liver fat, although useful, requires high
technical accuracy that may not be
achieved in all clinical settings. Cytoker-
atin-18 fragment, derived from a cysteine
endopeptidaseplayingaroleinregulating
inﬂammation and apoptosis, appears to
beagoodmarkerofNASH(52),although
Schwimmer commented that “this is not
perfecttechnologyyet.”ANAFLDﬁbrosis
risk score has been proposed using age,
BMI, diabetes, ALT, aspartic acid
transaminase (AST), platelets, and serum
albumin level (53), and there is evidence
that this can be made more accurate with
measurements of procollagen III and hy-
aluronic acid levels (54).
Given these caveats, it is important to
realize that NAFLD is associated with ad-
verse prognosis (55). Age-standardized
mortality is fourfold greater in subjects
with NAFLD based on liver biopsy; diag-
nosis based on ALT testing is associated
with1.5-foldincreaseinmortality(56).
This does not reﬂect liver disease alone.
Controlling for obesity, there is a strong
association of NAFLD with metabolic
syndrome factors (57), the development
of diabetes (58), coronary artery disease
mortality (59), and death from
malignancy.
Nathan Bass (San Francisco, Califor-
nia) discussed two current approaches to
the treatment of NASH, both based on its
hepatic prognosis, to prevent progression
to cirrhosis (at which point hepatic fat
may be reduced) and hepatocellular car-
cinoma. Because of this association and
the potential causative relationship of
NAFLD with CVD, Bass discussed recog-
nizing that NASH worsens hepatic IR.
NAFLD affects 12–15% of the U.S. pop-
ulation, 82% (30 million individuals)
withfattyliveralone,16.4%(6million)
with NASH, and 1.6% (600,000) with
cirrhosis. Over time, approximately 15–
30% of individuals with NASH progress
to cirrhosis. The presentation is typically
with an incidental ﬁnding of elevated
AST/ALT or with fatty liver on abdominal
imaging, but patients may present with a
complication of cirrhosis. Biopsy is useful
in determining the grade and stage of
NAFLD, allows greater conﬁdence in di-
agnosis, and may motivate the patient to
lose weight and guide intervention. Bi-
opsy is needed for participation in a treat-
ment trial. There is, however, some risk,
and biopsy may be inaccurate because of
sampling error. Furthermore, noninva-
sive diagnosis is relatively accurate, and
the natural history of NAFLD is benign in
most individuals, with no established
treatment beyond standard lifestyle inter-
ventions. Bass suggested that biopsy be
performed on subjects with age 45
years, diabetes, AST  ALT or ALT
three- to ﬁvefold above the upper limit
of normal, or difﬁculty excluding other
diagnoses in individuals who are not
obese and do not have metabolic syn-
drome.Ironoverload,ﬁndingssuggesting
cirrhosis, and support of a major treat-
ment decision such as bariatric surgery
would be additional indications.
The standard of care includes treat-
ment of dyslipidemia, hypertension, and
diabetes. Bass suggested that patients be
monitored for ALT, AST, alkaline phos-
phatase, bilirubin, albumen, prothrom-
bin time, platelet count (which he termed
a “foolproof early warning marker”) or
cirrhosis, and abdominal ultrasound,
and that patients be referred if there is
evidence of marked hepatic dysfunction.
Patients with NASH should avoid ex-
cessive acetaminophen, tamoxifen, amio-
darone, occupational solvents, iron supple-
ments, and vitamin A (in the absence of
deﬁciency). Some supplements, includ-
ing milk thistle, S-Adenosylmethionine
(SAMe), and betaine, appear safe. Al-
though alcohol, cannabis, and tobacco
should not be used, modest wine drink-
ing is associated with decreased preva-
lence of suspected NAFLD, which Bass
thought “is going to be very interesting.”
Statins are considered safe, and of course
may be beneﬁcial, based on a number of
studies in NAFLD.
According to Bass, speciﬁc interven-
tionsarebasedonthenotionthatprogres-
sion of NAFLD is due to “two hits” of
steatosis followed by many different se-
quential steps, such as oxidative stress
causing inﬂammation and leading to ﬁ-
brosis, which in turn gives rise to cirrho-
sis. He considered NAFLD “the hepatic
component of the metabolic syndrome,”
for which lifestyle modiﬁcation is appro-
priate. In a review of 10 studies of 626
patients, although only 123 had sequen-
tial biopsy, strong evidence of stabiliza-
tion or reversal of ﬁbrosis was lacking
with any intervention (60). In a study of
50 patients following a 1,500 calorie diet
and treated with vitamin E plus orlistat,
orlistat was not associated with greater
weight loss or other beneﬁt. Those pa-
tientswith4%weightlossdidshowim-
proved insulin sensitivity and reduction
in steatosis on biopsy at entry and at 36
weeks. Those with 8% weight loss also
showed improvement in ballooning and
inﬂammation. Although lack of physical
activity is undesirable, there is no evi-
dence that this is effective as an interven-
tion.Bariatricsurgeryhasbeenofinterest.
Malabsorptiveproceduressuchasjejuno-
ileal bypass are no longer used and
worsen liver disease, but restrictive and
Roux-en-Y tend to have favorable effects
with improvement in ﬁbrosis in 66% and
in fat and inﬂammation in 81% (61). No
pharmacologic treatment has been found
effective in long-term treatment. Bass
noted “the other confounding factor is
that there is a 15–30% placebo effect.”
Initial studies of treatment with met-
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evidence of improvement in histology.
There is experimental evidence that thia-
zolidinedionesimproveﬁbrosis,andclin-
ical studies suggest improvement in liver
enzymes (62). Although pioglitazone led
to greater reduction in steatosis and bal-
looning necrosis than placebo, there was
no clear reduction in ﬁbrosis. Bass de-
scribed a recently completed study of
247 patients with biopsy-proven NASH
randomizedtopioglitazone(30mg),vi-
tamin E, or placebo for 96 weeks. In the
study, ALT and AST improved with
both active treatments and IR improved
with pioglitazone, but there was weight
gain with pioglitazone and histologic
improvement was greater with vitamin
E. Neither signiﬁcantly improved ﬁbro-
sis (63). IR, then, is important, “but not
the whole story,” said Bass. Other hepa-
toprotective strategies must be ex-
plored, with “ﬁbrosis … a tough end
point but … the one that matters most,”
he said.
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